Drug interactions
Deferasirox + Pacritinib
Severity: Moderate
Deferasirox and Pacritinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Pacritinib is metabolized by CYP3A4, and deferasirox can modestly induce CYP3A4, possibly lowering pacritinib exposure. This could reduce efficacy in myelofibrosis.
What this interaction means in plain words
Deferasirox and Pacritinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Deferasirox belongs to Miscellaneous; Pacritinib belongs to Oncology.
Why it happens
Deferasirox may induce CYP3A4, increasing pacritinib clearance.
What to do
Monitor spleen and symptom response to pacritinib when starting or stopping deferasirox. Consider an alternative chelator if response declines.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Deferasirox and Pacritinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Deferasirox
Other interactions of Pacritinib
- Clarithromycin + Pacritinib Contraindicated
- Ketoconazole + Pacritinib Contraindicated
- Pacritinib + Posaconazole Contraindicated
- Pacritinib + Voriconazole Contraindicated
- Amiodarone + Pacritinib Major
- Carbamazepine + Pacritinib Major
Frequently asked questions
Can I take Deferasirox with Pacritinib?
MediHelp rates the interaction as moderate. Deferasirox and Pacritinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Pacritinib is metabolized by CYP3A4, and deferasirox can modestly induce CYP3A4, possibly lowering pacritinib exposure. This could reduce efficacy in myelofibrosis.
How serious is the interaction between Deferasirox and Pacritinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor spleen and symptom response to pacritinib when starting or stopping deferasirox. Consider an alternative chelator if response declines.
What other medicines interact with Deferasirox?
MediHelp also lists interactions of Deferasirox with, for example, Acetylsalicylic acid, Alosetron, Aluminum hydroxide. The full list is on the Deferasirox page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
